- Report of University Hospital Hradec Králové to the clinical trial protocol No: OPH1002Publication without faculty affiliation
- Benefical effect pars plana vitrectomy in Macugen and Lucentis as a treatment only seeing eye patiens with haemorhagic glaucoma due to CRVOPublication without faculty affiliation
- Ranibizumab (Lucentis) in the Treatmnet of Age-Related Macular Degeneration +12009 | Faculty of Medicine in Hradec Králové
- Ranibizumab (Lucentis) in the Treatmnet of Age-Related Macular Degeneration2009 | First Faculty of Medicine
- Favourable Effect of Pars Plana Vitrectomy with Macugen and Lucentis Application as the Treatment of only One Eye with Haemorrhagic Glaucoma due to Central Retinal Vein OcclusionPublication without faculty affiliation
- Lucentis In The Treatment Of Diabetic Macular Edema, Two-Year Results2022 | Faculty of Medicine in Hradec Králové
- Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration2019 | Faculty of Medicine in Hradec Králové
- Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration2023 | Publication without faculty affiliation